Close

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

November 7, 2022 8:00 AM EST

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022.

Guggenheim 4th Annual Immunology and Neurology Day fireside chat details:
  
Date:Monday, November 14th, 2022
  
Time:3:55 pm Eastern Time
  
Webcast:The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com

Contact:Chau Cheng, PhD, MBAVice President, Investor RelationsImmunovant, Inc.[email protected] 

Source: Immunovant Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Guggenheim